Tung S, Davis LE, Hallet J, et al. - In this population-based cohort study of 615 patients with pancreatic adenocarcinoma (PA), researchers focused on symptom burden and trajectories and factors related to high symptom burden after pancreaticoduodenectomy (PD) for PA. Moderate to severe symptoms (defined as Edmonton Symptom Assessment System ≥ 4) for anxiety, depression, drowsiness, lack of appetite, nausea, pain, shortness of breath, tiredness, and impaired well-being were mainly assessed. In this largest cohort describing symptom burden for this population, the observed prevalence of symptoms after PD for PA was high, though improvement was seen over the first 3 months postoperation. Symptoms that were most commonly reported as moderate to severe included tiredness (443 [72%]), impaired well-being (418 [68%]), and lack of appetite (400 [65%]). A higher risk of reporting moderate to severe symptoms was observed in relation to female gender, higher comorbidity, and lower income. There was no link between receipt of adjuvant chemotherapy and the risk of moderate to severe symptoms.